New York—Glenna Goldis, a former attorney for New York Attorney General Letitia James, has been hired by the Federal Trade Commission (FTC) after being dismissed from her position earlier this year. Goldis has attracted attention for her outspoken criticism of “gender-affirming care” for minors, a stance that reportedly led to her firing.

Describing herself as a “lefty lesbian lawyer,” Goldis challenged the practices surrounding puberty blockers and cross-sex hormones for children during her tenure as an assistant attorney general in the consumer fraud bureau. Her comments sparked conflict with James, after which Goldis became increasingly vocal about her concerns regarding pediatric gender medicine.

In a July FTC roundtable discussion on transgender medical procedures, she stated that the definition of gender identity, as interpreted by medical professionals, lacks clarity. “Gender identity, the way it is defined by gender doctors, has no definition,” she asserted, aiming to address what she sees as problematic language in the healthcare industry.

Goldis’s outspoken views prompted her dismissal in January when James’s office described her public commentary as detrimental to their mission and credibility. She later expressed that her concerns about pediatric gender medicine were treated as mere annoyances by her former colleagues.

Following her termination, Goldis took to social media, revealing her dismissal due to her critique of pediatric gender medicine. Her remarks emphasized her belief that some healthcare providers may engage in consumer fraud regarding treatments for gender identity issues.

In her new role at the FTC, Goldis will serve as a senior litigator within the Bureau of Consumer Protection, where she is expected to lead investigations into the safety and efficacy of practices related to “gender-affirming care.” Joe Simonson, the FTC’s Director of Public Affairs, praised her as a knowledgeable and courageous addition to the team, expressing enthusiasm for her contributions to consumer protection efforts.

Goldis has also continued to articulate her views publicly, using platforms like Substack to delve into her experiences and criticisms of James’s policies. In one of her writings, she emphasized the importance of questioning the motivations behind gender-affirming treatments and the language surrounding them.

As Goldis embarks on this new chapter with the FTC, her previous controversies are likely to remain a focal point of scrutiny in both legal and public discussions surrounding gender-related healthcare practices.